La cadena de opciones muestra datos clave de las opciones de acciones de Connexa Sports Techs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Connexa Sports Techs..

Connexa Sports Techs (NASDAQ:YYAI) Bolsa, Cadena de Opciones

Connexa Sports Technologies Inc. - Common Stock

Connexa Sports Technologies Inc operates in the sports equipment and technology business. It is a connected sports company delivering products, technologies, and services across the Watch, Play, Learn commercial and subscription-as-a-service activities in sports. The company's offerings include Slinger Launcher, which is comprised of a portable tennis ball launcher, a portable padel tennis ball launcher, and a portable pickleball launcher. Through Gameface, it provides AI technology and performance analytics.

Connexa Sports Technologies Inc

Benchmark analyst David Williams maintains Alpha &amp; Omega (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) with a Buy and lowers the price target from $42 to $32.

News

Price Target

Analyst Ratings

AOSL

Benchmark Maintains Buy on Alpha & Omega, Lowers Price Target to $32

WIIM

PSIX

Power Solutions International shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Barclays analyst Adrienne Yih maintains Crocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) with a Overweight and lowers the price target from $122 to $119.

CROX

Barclays Maintains Overweight on Crocs, Lowers Price Target to $119

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Tycho Peterson upgraded the rating for GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) from Hold to Buy and announced a target of $80. GeneDx shares closed at $56.36 on Thursday. <a href="https://www.benzinga.com/quote/wgs/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Paul Lejuez upgraded the rating for National Vision Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) from Neutral to Buy and raised the price target from $13 to $21. National Vision shares closed at $16.68 on Thursday. <a href="https://www.benzinga.com/quote/eye/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Tazeen Ahmad upgraded PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Neutral to Buy and raised the price target from $55 to $68. PTC Therapeutics shares closed at $42.51 on Thursday. <a href="https://www.benzinga.com/quote/ptct/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying EYE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="614" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106-1024x614.png" alt="" class="wp-image-910039" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106-1024x614.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106-768x460.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09081454/image-106.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Markets

Trading Ideas

CVRX

PTCT

WOLF

This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday

IBEX

IBEX shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.

REAL

RealReal shares are trading lower following Q1 financial results.

Needham analyst Ryan Koontz maintains Adtran Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTN#NASDAQ">ADTN</a>) with a Buy and lowers the price target from $14 to $12.

ADTN

Needham Maintains Buy on Adtran Holdings, Lowers Price Target to $12

Barclays analyst Gena Wang maintains CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Equal-Weight and lowers the price target from $56 to $42.

CRSP

Barclays Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $42

B of A Securities analyst Sachin Salgaonkar downgrades Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) from Buy to Neutral and maintains the price target from $160 to $160.

Downgrades

B of A Securities Downgrades Sea to Neutral, Maintains Price Target to $160

WULF

TeraWulf shares are trading lower after the company reported worse-than-expected Q1 financial results.

Barclays analyst Matthew Bouley maintains Compass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) with a Equal-Weight and lowers the price target from $9 to $8.

COMP

Barclays Maintains Equal-Weight on Compass, Lowers Price Target to $8

TIXT

TELUS International shares are trading higher after the company reported better-than-expected Q1 financial results.

HC Wainwright &amp; Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) with a Buy and raises the price target from $21 to $22.

ORIC

HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $22

Alpha Metallurgical Resources shares are trading lower after the company reported Q1 financial results and missed its EPS and sales estimates.

B of A Securities analyst Tazeen Ahmad upgrades PTC Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) from Neutral to Buy and raises the price target from $55 to $68.

B of A Securities Upgrades PTC Therapeutics to Buy, Raises Price Target to $68

Barclays analyst Richard Hightower maintains Camden Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPT#NYSE">CPT</a>) with a Overweight and raises the price target from $127 to $136.

Barclays Maintains Overweight on Camden Prop Trust, Raises Price Target to $136

MGTX

MeiraGTx Holdings shares are trading higher after the company announced it was granted an FDA regenerative medicine advanced therapy designation for its AAV-GAD treatment of parkinson's disease.

Needham analyst Bernie McTernan maintains Compass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) with a Buy and lowers the price target from $12 to $11.

Needham Maintains Buy on Compass, Lowers Price Target to $11

Barclays analyst Betty Jiang maintains California Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) with a Equal-Weight and raises the price target from $47 to $50.

Barclays Maintains Equal-Weight on California Resources, Raises Price Target to $50

BMO Capital analyst Rufus Hone downgrades International Money (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMXI#NASDAQ">IMXI</a>) from Outperform to Market Perform and lowers the price target from $18 to $11.

IMXI

BMO Capital Downgrades International Money to Market Perform, Lowers Price Target to $11

Press Releases

Connexa Regains Full Nasdaq Compliance

Connexa Reports FY 2024 Audited Financial Results and Provides Review of Operations

Yuanyu Enterprise Management Co., Limited, Reports 1Q2024 Unaudited Financial Results

Yuanyu Enterprise Management announces entry into an exclusive license agreement for its innovative matchmaking technology covering the UK and Europe

Yuanyu Enters $4 Billion Matchmaking Market, Signs $30 Million Licensing Agreement

CONNEXA RECEIVES NASDAQ APPROVAL TO ACQUIRE YUANYU ENTERPRISE MANAGEMENT

CORRECTION NOTICE OF PRESS RELEASE ANNOUNCING RECEIPT OF NASDAQ APPROVAL TO ACQUIRE YUANYU ENTERPRISE MANAGEMENT

CONNEXA HAS CLOSED THE ACQUISITION OF A FURTHER 50% OF YYEM AND CONFIRMS THAT TRADING OF THE POST-ACQUISITION YYAI WILL COMMENCE FRIDAY, NOVEMBER 22, 2024

Connexa Sports Technologies Inc. Expands into Social Networking and Content Creation and Enters Discussions with TikTok in the Middle East and North Africa

Comments

Connexa Sports Techs

Connexa Sports Techs (YYAI) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL